First-pass extracted concept

NMDA receptor antagonists

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

NMDA blockade, N-methyl-D-aspartate receptor antagonists

Extracted Explainers

What the tool is doing

This review treats NMDA receptor antagonism as a shared perturbation that can produce schizophrenia-like effects and, in some contexts, antidepressant effects. The abstract frames the class as a mechanistic lens rather than a single tool.

Source 1DOI PubMed

What problem it solves

It helps explain how similar NMDA-blocking interventions can be associated with different neuropsychiatric outcomes. The review uses it to connect schizophrenia models and ketamine-responsive depression.

Source 1DOI PubMed

What it does not solve

The abstract does not provide a precise operational method for separating beneficial from psychotomimetic effects. It also does not specify a concrete engineering or assay protocol.

Source 1DOI PubMed

Alternatives

The abstract names specific antagonists within this class rather than contrasting against non-NMDA approaches.

Source 1DOI PubMed

Evidence Snippets

N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP), dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia, both in animals and humans.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2020BiomoleculesDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1disease model rolesupports2020Source 1DOI PubMed

NMDA receptor antagonists such as PCP, MK-801, and ketamine have long been considered a model of schizophrenia in animals and humans.

Quoted textsource-backed

N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP), dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia, both in animals and humans.

Claim 2mechanistic interpretationsupports2020Source 1DOI PubMed

The review postulates that NMDA receptor antagonists induce similar mechanistic effects and that the organism's basal pre-drug state delimits the overall outcome.

Quoted textsource-backed

Here, we describe the temporal mechanisms implicated in schizophrenia-like and antidepressant-like effects of NMDA blockade in rats, and postulate that such effects may indicate that NMDA receptor antagonists induce similar mechanistic effects, and only the basal pre-drug state of the organism delimitates the overall outcome.

Claim 3state dependent outcomesupports2020Source 1DOI PubMed

NMDA receptor blockade can improve symptoms in depressive-like status, while causing psychotic symptoms in healthy individuals and exacerbating symptoms in schizophrenia patients.

Quoted textsource-backed

Hence, blockade of NMDA receptors in depressive-like status can lead to amelioration or remission of symptoms, whereas healthy individuals develop psychotic symptoms and schizophrenia patients show an exacerbation of these symptoms after the administration of NMDA receptor antagonists.

Claim 4temporal effect ordersupports2020Source 1DOI PubMed

At similar dosage, positive symptoms of schizophrenia appear before antidepressant effects emerge after NMDA antagonist exposure.

Quoted textsource-backed

Interestingly, the dosage in both conditions is similar, and positive symptoms of schizophrenia appear before antidepressant effects emerge.